AKT1 and cancer: The expression of YB1 is usually associated with resistance to platinum drugs (such as cisplatin) and also promotes the malignant progression of cancer cells and acquisition of drug resistance by regulating genes involved in cell proliferation and the cell cycle, such as EGFR and HER2 (62–66); targeting the AKT/mTOR/p70S6k or MEK/ERK/p90RSK signaling pathways to inhibit downstream YB1 activity can inhibit tumor drug resistance (67) (Figure 3).